The influence of interleukin-6 on the course of ovarian cancer
In Poland, in 2015, according to the National Cancer Registry (NCR), cancer was diagnosed among 163 281 people, including 81 632 women and 81 649 men. Ovarian cancer in 2015 affected 3% of women who had cancer. Interleukin 6 is a glycoprotein that consists of 212 amino acids. The gene encoding interleukin 6 is located on chromosome 7 adjacent to the gene LOC541472 and RSP26P32 in 7p15.3. The sources of interleukin 6 include tumor cells and macrophages that are secreted by bone marrow cells as a result of a process in which monoblasts are transformed into the promonocyte in the bone marrow, and the next monocytes into the macrophage in the blood. Scientific evidence points to an increase of IL-6 in blood by about 10 pg/ml in relations to healthy people and the increased expression of the encoding gene IL-6 by 2.2 in cancer tissue in relation to healthy tissue. The authors of the studies carried out so far do not indicate a connection between the concentration of IL-6 in the blood and the size of the tumor according to the FIGO classification, and predict a shorter survival time for patients with an increased level of IL-6. Mutation in the encoding gene IL-6 174 G>C according to the previously collected research results does not affect the patients’ expected life expectancy. There are no research results that would indicate that the mutation in the IL-6 gene affects its concentration in the blood or the level of gene expression that is responsible for its coding.
2. Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin-6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-expressing regulatory T cells. Front Immunol. 2017; 8:148
3. Sanguinete MMM, Oliveira PH, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, Nomelini RS. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. 2017; 46(7): 677-688.
4. Krajowy rejestr nowotworów. http://onkologia.org.pl/nowotwory-jajnika-c56/ (accessed 27.12.2018).
5. Basta A, Bidziński M, Bieńkiewicz A, Blecharz P, Bodnar L, Jach R, et al. Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka jajnika. Curr Gynecol Oncol. 2017; 15(1): 5-23.
6. Nowak-Markiewitz E, Spaczyński M. Rak jajnika - nowe spojrzenie na pochodzenie i histogenezę. Ginekol Pol. 2012; 83: 454-457.
7. Isobe A, Sawada K, Kinose Y, Ohyagi-Hara C, Nakatsuka E, Makino H, et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One. 2015; 10(2): e0118080.
8. Chechlińska M. Rola cytokin w procesach nowotworzenia. Nowotwory. Journal of Oncology. 2003; 53(6): 648-659.
9. Kishimoto I, Tanaka T. Interleukin 6. Encyclopedia of inflammatory diseases. DOI: 10.1007/978-3-0348-0620-6_179-1
10. Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995; 7(6): 542-547.
11. Erroi A, Sironi M, Chiaffarino F, Chen ZG, Mengozzi M, Mantovani A. IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer. 1989; 44(5): 795-801.
12. Gene: https://www.ncbi.nlm.nih.gov/gene/3569 (accessed 27.12.2018).
13. Kumar J, Ward AC. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta. 2014; 1845(2): 117-125.
14. Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw. 2013; 24(3): 106-113.
15. Mądry R, Markowska J, Sobieska M. 51P Interleukina-6 i rozpuszczalny receptor interleukiny-6 u chorych na raka jajnika. Reports Pract Oncol Radiother. 1998; 3(suppl. 1): 59.
16. Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL. Intratumoral interleukin6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring. J Ovarian Res. 2015; 8: 58.
17. Kolomeyevskaya N, Eng KH, Khan ANH, Grzankowski KS, Singel KL, Kirsten M, Segal BH. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138: 352-357.
18. Zhai K, Yang Y, Gao ZG, Ding J. Interleukin-6-174 G>C gene promoter polymorphism and prognosis in patients with cancer. Oncotarget. 2017; 8(27): 44490-44497.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.